Due to the great progress and development of modern technology, our understanding of neuropsychiatric disorders biological, physiological, and metabolic processes has advanced tremendously. However, we still face many challenges in drug discovery and development targeting because neuropsychiatric disorders have a complex etiology with multiple points of possible intervention. This is also apparent in consideration of the plurality of targets that bind antipsychotics, anti-Parkinsonian, or antidepressant drugs, indicating the need to develop multi-target compounds for a polypharmacological approach (Hopkins, 2008) .
Understanding the interactions of neurotransmission systems especially among monoamines is an important step for the optimization of therapeutic strategies for many if not all of these neuropsychiatric disorders. Neurotransmitters such as dopamine, serotonin, noradrenaline or histamine play a central role in the pathophysiology of major neuropsychiatric illnesses, including anxiety and mood disorders, schizophrenia, autism-spectrum disorders, Parkinson's disease, epilepsy, and dementias (De Deurwaerdère & Di Giovanni, 2016; Simic et al., 2016; Venzi et al., 2016) . Numerous medicines targeting monoaminergic systems have been used successfully but most require adjustments due to the emergence of side effects.
However, the efficacy of these medicines stress that the strategy to correct abnormal signalling of monoaminergic neurotransmitters is appropriate. A further complication arises in that monoaminergic systems establish close relationships with other neurotransmitter systems (Chesselet, 1984) , so it is likely that a pharmacological action toward one system will more or less directly affect the other one. This is highlighted by well-known associations such as the 5-HT/DA interaction (De Deurwaerdère & Di Giovanni, 2016; , the glutamate/DA interaction (Carlsson & Carlsson, 1990) , and the 5-HT/GABA interaction (Crunelli & Di Giovanni, 2014; Soubrie, 1986) The purpose of this special issue is to collect relevant research and review papers covering the wide spectrum of the neuropathology and neuropharmacology of monoaminergic systems. Guiard and colleagues (Zemdegs et al., 2016) report on the bidirectional link between type 2 diabetes mellitus (T2DM) and depression. These Two contributions from Bortolato and colleagues (Godar et al., 2015) are studies focused on dopamine and its receptors in the regulation of prepulse inhibition (PPI) of the acoustic startle, a well-known cross-species index of sensorimotor gating, typically impaired in several neuropsychiatric disorders featuring dopaminergic imbalances, such as Tourette syndrome (TS), schizophrenia and mania. D1CT-7 mice, one of the best-characterized animal models of TS, exhibit PPI deficits in response to short-term spatial confinement (SC). These D1CT-7 mice are characterized by a neuropotentiating transgene in select populations of neurons containing D1 dopamine receptors, and exhibit specific tic-like responses. A mild environmental stressor also produced a significant exacerbation in tic-like responses, in a fashion sensitive to benchmark therapies for TS. Taken together, their data highlight a novel experimental platform to study the neurobiological links between environmental stress and TS manifestations (including tic-like responses) in animal models. The second study showed that hooded Long-Evans rats display PPI deficits in response to the selective activation of both D1 and D2 dopamine receptors.
Conversely, only D2 agonists have PPI-disrupting properties in Sprague-Dawley and
Wistar albino rats. One of the first-documented examples of D1 sensitivity in PPI in rats, this model may prove valuable to study the involvement of the D1 receptor in rat models of TS, schizophrenia and mania.
Moving more to studies where the interactions of the neurotransmission systems are relevant to degeneration, De Deurwaerdère and Ugedo (Miguelez et al., 2016) focused on the effect of the L-DOPA, the gold standard medication of Parkinson's disease, on serotonergic system. L-DOPA therapeutic superiority compared to other medication is impaired by numerous side-effects including dyskinesia. Agonists at 5-HT1A receptors can reduce L-DOPA-induced dyskinesia but these compounds have their own side-effects (Carta et al., 2007) . Indirectly, the selective serotonin reuptake inhibitors could stimulate 5-HT1A receptors but their efficacy could be lowered due to the own effects of L-DOPA on serotonergic neuron activity (Navailles et al., 2011) .
Here, Miguelez et al. (2016) studied the acute and long-term L-DOPA effects and the activity of dorsal raphe serotonergic neurons in 6-OHDA-lesioned rats, a preclinical model of Parkinson's disease. They found that the 5-HT1A receptor-dependent control of serotonergic neurons is unaltered in dyskinetic rats and that the SSRI fluoxetine loses its efficacy to inhibit the 5-HT1A receptor-dependent inhibitory control of serotonergic neurons in the presence of L-DOPA. This study raises caution to the use of SSRI in the treatment of depression or dyskinesia in L-DOPA-treated Parkinsonian patients (Miguelez et al., 2016) Also relevant to dyskinesia in Parkinson's disease, is a review (García et al., 2016) Ponimaskin and Kondaurova and their colleagues (Kulikova et al., 2016) The final article looks beyond the neurotransmitter systems to other factors affecting neuronal survival in the face of ageing and neurodegenerative diseases. Youdim and colleagues (Weinreb et al., 2015) reviewed the neuroprotective effects of hybrid agents targeting MAOs, cholinesterases, iron load, and β-amyloid accumulation in ageing and AD. Nowadays, AD is accepted as a complex neurodegenerative disorder with multifaceted cerebral pathologies and it is widely accepted that an effective therapy for AD could result from the use of multifunctional drugs affecting more than one target involved in the disease pathology. The potential benefits of novel multimodal neuroprotective, brain-permeable drugs, recently developed by Youdim and collaborators, are a valuable therapeutic approach for AD treatment.
The key message from these studies is the cross-talk between systems. Fundamental research to identify key proteins that influence the functional pathways is essential for future multi-target drug design. In turn, multi-target compounds will aid the dissection of the complex pathways in neuropharmacology and our understanding of how the brain works and how best to normalise its function.
